ABSTRACT
BACKGROUND: Although insulinomas are very rare tumors, they are the most common pancreatic neuroendocrine neoplasms. The incidence in general population is 1-4 per 1,000,000 yearly but the incidence is higher in autopsy studies. The malignancy of insulinomas is difficult to be predicted on the basis of their histological features, and the current WHO classification has been re-evaluated. This review aimed to summarize classical knowledge with current trends in the diagnosis and treatment of insulinomas. DATA SOURCES: A Medline search using terms "insulinoma", "treatment" and "neuroendocrine tumors" was conducted. Additional references were sourced from key articles. RESULTS: Surgery is the treatment of choice for insulinoma and has an extremely high success rate. Medical treatment is also available but only for patients who are unable or unwilling to undergo surgical treatment. Preoperative localization is necessary for planning the surgical approach. Many methods exist for localization of an insulinoma and can be invasive and non-invasive. The combination of biphasic thin section helical CT and endoscopic ultrasonography (EUS) has an almost 100% sensitivity in localizing insulinomas. Laparoscopic ultrasound is mandatory to localize intraoperatively these tumors. EUS-guided fine needle tattooing is an alternative method of localization in case of lack of laparoscopic ultrasound. CONCLUSION: Laparoscopic resection for benign insulinomas is the procedure of choice, whereas pancreatectomy is reserved for large, potentially malignant tumors.
Subject(s)
Diagnostic Imaging/trends , Digestive System Surgical Procedures/trends , Insulinoma , Pancreatic Neoplasms , Biopsy, Fine-Needle/trends , Diagnostic Imaging/history , Digestive System Surgical Procedures/history , Endosonography/trends , History, 20th Century , Humans , Insulinoma/diagnosis , Insulinoma/history , Insulinoma/surgery , Laparoscopy/trends , Pancreatectomy/trends , Pancreatic Neoplasms/diagnosis , Pancreatic Neoplasms/history , Pancreatic Neoplasms/surgery , Patient Selection , Predictive Value of Tests , Tomography, Spiral Computed/trends , Treatment OutcomeABSTRACT
Insulinomas are functional endocrine tumors originating from the pancreatic b-cells. In 1902 Nicholls described the first adenoma of pancreatic islets, while the first insulinoma was described in 1927 in Mayo Clinic, which was dissected two years later in 1929 in Toronto. The first enucleation of insulinoma took place in a St. Jouis hospital in 1931, and after four years, in 1935, Whipple described the classic diagnostic triad: symptoms of fasting hypoglycemia or fatigue, blood glucose levels under 50 mg/dl and disappearance of symptoms after glucose administration.
